The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Reactive oxygen species are important mediators for platelet-derived growth factor (PDGF) signaling in vascular smooth muscle cells, whereas excess reactive oxygen species-induced oxidative stress contributes to the development and progression of vascular diseases, such as atherosclerosis. Activation of the redox-sensitive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2), is pivotal in cellular defense against oxidative stress by transcriptional upregulation of antioxidant proteins. This study aimed to elucidate the role of Nrf2 in PDGF-mediated vascular smooth muscle cell migration and neointimal hyperplasia. Approach and Results-PDGF promoted nuclear translocation of Nrf2, followed by the induction of target genes, including NAD(P)H:quinone oxidoreductase-1, heme oxygenase-1, and thioredoxin-1. Nrf2 depletion by small interfering RNA enhanced PDGF-promoted Rac1 activation and reactive oxygen species production and persistently phosphorylated downstream extracellular signal-regulated kinase-1/2. Nrf2 depletion enhanced vascular smooth muscle cell migration in response to PDGF and wound scratch. In vivo, Nrf2-deficient mice showed enhanced neointimal hyperplasia in a wire injury model. Conclusion-These findings suggest that the Nrf2 system is important for PDGF-stimulated vascular smooth muscle cell migration by regulating reactive oxygen species elimination, which may contribute to neointimal hyperplasia after vascular injury. Our findings provide insight into the Nrf2 system as a novel therapeutic target for vascular remodeling and atherosclerosis. (Arterioscler Thromb Vasc Biol. 2013;33:760-768.)
R eactive oxygen species (ROS), including superoxide anion and hydrogen peroxide, have been recognized as intracellular signaling molecules and are involved in physiological repair processes, including wound healing and angiogenesis. 1, 2 However, oxidative stress caused by increased ROS plays an important role in the pathogenesis of cardiovascular diseases. Several studies have reported an increase in ROS generation during restenosis after angioplasty 3, 4 and an impairment of neointimal hyperplasia by antioxidants. 5 In addition, risk factors for the development of atherosclerosis and stenosis (eg, hyperglycemia, hypertension, and hyperlipidemia), mediate elevated ROS levels in the vasculature. 6 Thus, cellular defense against oxidative stress is critical for maintaining vascular homeostasis.
Abnormal growth of the intimal layer of blood vessels in response to injury is a key event in the development of vascular occlusive diseases. Platelet-derived growth factor (PDGF) stimulates vascular smooth muscle cell (VSMC) migration and proliferation primarily through PDGF receptor-β (PDGFR-β), thereby contributing to neointimal formation and vascular remodeling in vivo. 7 In VSMCs, PDGF binding initiates PDGFR-β autophosphorylation, followed by the activation of key signaling enzymes, including p44/42 mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinase-1/2 (ERK1/2), p38 MAPK, and the cell survival kinase Akt. 1, 8 Furthermore, PDGF activates the small GTPase Rac1 that is important for the activation of NAD(P)H oxidase, a major source of ROS in VSMCs. 2, 9 PDGF-induced migration is reportedly inhibited by pretreatment with extracellular catalase, implicating ROS as mediators of VSMC migration. 10 Therefore, it is generally considered that the blocking of oxidative stress-induced VSMC hyperactivation is a useful therapeutic intervention for attenuating the incidence of most vascular diseases.
Because excess ROS induce oxidative damage, cellular redox balance is tightly controlled by various antioxidant systems. Nuclear factor erythroid 2-related factor 2 (Nrf2), a basic leucine zipper transcription factor, plays a critical role in the cellular defense system by mediating the coordinated upregulation of antioxidant responsive element (ARE)-driven detoxification and antioxidant genes. 11 In the presence of oxidative stress, Nrf2 translocates to the nucleus, where it forms the Nrf2/small Maf heterodimer and binds specifically to ARE, and activates gene expression of phase II detoxification enzymes and antioxidant proteins, such as NAD(P)H:quinone oxidoreductase-1 (Nqo1), heme oxygenase-1 (Hmox1), and thioredoxin-1 (Txn1). 12 Many studies have reported a pathophysiological role of Nrf2 in protecting cells from oxidative stress. For example, Nrf2-deficient (−/−) mice are more susceptible to allergen-induced asthma, 13 cutaneous wound repair, 14 and lupus-like autoimmune nephritis. 15 In endothelial cells, laminar shear stress, an antiatherogenic flow, promotes Nrf2 nuclear accumulation and induces Nrf2-ARE-regulated genes, including Nqo1 and ferritin heavy chain, whereas oscillatory shear stress, a proatherogenic flow, also promotes Nrf2 nuclear accumulation but prevents Nrf2 from binding to ARE. 16 Nrf2 nuclear localization increases in the endothelium in atherosclerosis-resistant regions of the mouse aorta. 17 Furthermore, the Nrf2-dependent gene Hmox1 reduces the chemotaxis of VSMCs after exposure to PDGF. 18 These reports presume that Nrf2 alter susceptibility to atherosclerosis. However, a direct role of Nrf2 in PDGF-induced VSMC migration and the neointimal hyperplasia response to vascular injury have not been demonstrated.
In this study, we demonstrated that Nrf2 knockdown by small interfering RNA (siRNA) enhanced VSMC migration in response to PDGF and wound scratch. Mechanistically, PDGF stimulation promoted Nrf2 nuclear translocation and induced Nqo1, Hmox1, and Txn1 gene expression. PDGF was associated with increased cellular ROS levels and Rac1 activity, which were enhanced by Nrf2 siRNA. Furthermore, VSMCs depleted of Nrf2 exhibited prolonged downstream ERK1/2 phosphorylation. In vivo, an increase in Nrf2 was observed by immunohistochemical analysis at neointimal lesions in a wire injury model. The Nrf2 −/− mice showed enhanced neointimal hyperplasia. These findings suggest that Nrf2 regulates ROS-dependent PDGF signaling, thereby regulating VSMC migration, which may contribute to neointimal formation after vascular injury.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

PDGF Promotes Nrf2 Nuclear Translocation, Thereby Inducing Nrf2 Target Genes in VSMCs
Nrf2 translocates to the nucleus in response to ROS, thereby inducing antioxidant proteins, including Nqo1, Hmox1, and Txn1. 12 PDGF significantly increased intracellular ROS levels 5 minutes after treatment, reached peak levels at 15 minutes, and returned to control levels by 60 minutes ( Figure IA in the online-only Data Supplement). We therefore examined whether PDGF promotes Nrf2 nuclear translocation, thereby inducing antioxidant gene expression. As shown in Figure 1A (color pictures are available in Figure IB in the online-only Data Supplement), in untreated rat VSMCs (RASMCs), Nrf2 was found in the cytoplasm and nucleus. PDGF stimulation for 60 minutes promoted Nrf2 translocation from the cytoplasm to the nucleus. We confirmed actively migrating VSMC by staining with phalloidin, an F-actin marker. Actively migrating VSMCs formed lamellipodia and stress fiber. Furthermore, PDGF induced Hmox1 mRNA at 4 hours, and Nqo1 and Txn1 mRNA at 16 hours after the treatment ( Figure 1B ).
Nrf2 Depletion Enhances PDGF-Stimulated VSMC Migration but not VSMC Proliferation
To determine the functional significance of Nrf2, we examined the effects of Nrf2 siRNA on PDGF-induced VSMC migration. Transfection of VSMCs with Nrf2 siRNA significantly reduced endogenous Nrf2 expression (Figure 2A and 2B) and downregulated basal levels of Nqo1, Hmox1, and Txn1 expression ( Figure 2A and Figure II in the online-only Supplement). Modified Boyden chamber assays demonstrated that knockdown of endogenous Nrf2 expression by siRNA significantly enhanced migration stimulated by low-dose (10 ng/mL) and high-dose (25 ng/mL) PDGF in VSMCs ( Figure 2C ). Wound scratch assays of confluent monolayers of VSMCs in the presence of PDGF also showed that Nrf2 siRNA significantly enhanced directional cell migration in response to wound injury ( Figure 2D ). Furthermore, pretreatment of Nrf2 siRNA-treated VSMCs with apocynin, an antioxidant, inhibited migration stimulated by PDGF ( Figure III in the online-only Data Supplement). In contrast, transfection of Nrf2 siRNA did not have a significant effect on PDGFinduced VSMC proliferation ( Figure IV in the online-only Data Supplement). These results suggest that Nrf2 plays a role in PDGF-stimulated VSMC migration.
Nrf2 Is Involved in PDGF-Increased ROS Levels and Rac1 Activity in VSMCs
To gain insight into the mechanism by which Nrf2 regulates VSMC migration in response to PDGF, we examined whether Nrf2 is involved in modulating ROS levels. As shown in Figure 3A (color pictures are available in Figure V in the online-only Supplement), PDGF increased intracellular ROS levels in the control siRNA-transfected cells and in the Nrf2knockdown cells. In the control siRNA-transfected cells, ROS levels peaked 15 to 30 minutes after PDGF stimulation and then returned to prestimulation levels by 60 minutes, similar to the results in Figure IA (available in the onlineonly Data Supplement), whereas Nrf2 knockdown by siRNA significantly prolonged the elevation of intracellular ROS levels in response to PDGF stimulation.
A major source of PDGF-induced ROS in VSMCs is NAD(P)H oxidase, which is activated through Rac1 GTPase. 2, 9 We therefore examined the effect of PDGF on Rac1 activation. PDGF rapidly activated Rac1 within 2 minutes, and the activation persisted for 30 minutes ( Figure VI in the online-only Data Supplement). Because Nrf2 was involved in PDGF-enhanced ROS levels, we next examined the effect of Nrf2 knockdown by siRNA on PDGF-induced Rac1 activation. As shown in Figure 3B , PDGF activated Rac1 in the control siRNA-transfected cells and in the Nrf2-knockdown cells. Interestingly, the Nrf2-knockdown cells exhibited significantly elevated levels of both basal and PDGF-simulated Rac1 activity compared with the control cells. These results suggest that loss of Nrf2 function increases PDGF-induced oxidative stress in VSMCs.
Nrf2 Depletion Prolongs the Duration of PDGF-Enhanced ERK1/2 Phosphorylation in VSMCs and Antioxidants Inhibit ERK1/2 Phosphorylation
Because PDGF-induced ROS levels were enhanced by Nrf2 knockdown ( Figure 3A ), we examined whether Nrf2 involved in the activation of key downstream signaling enzymes in response to PDGF. As shown in Figure 4A , PDGF-induced ERK1/2 phosphorylation peaked at 5 minutes, and then fell to 43.5% of the peak level at 60 minutes in the control siRNAtransfected RASMCs. In the Nrf2-knockdown cells, the effect of PDGF on ERK1/2 phosphorylation persisted, and the phosphorylated ERK1/2 level was significantly higher than that in the control cells at 30 to 60 minutes. In contrast, PDGFenhanced PDGFR-β phosphorylation and the other signaling molecules p38 MAPK and Akt were not affected by Nrf2 siRNA ( Figure VII in the online-only Data Supplement). Importantly, we found that PDGF-induced ERK1/2 phosphorylation was inhibited by antioxidants, including N-acetylcysteine (NAC), a radical scavenger, and apocynin, an NAD(P)H oxidase inhibitor, suggesting that ERK1/2 is a redox-sensitive kinase in the PDGF signaling pathway ( Figure 4B ).
Nrf2 Is Increased In Vivo in Neointimal Lesions in Response to Vascular Injury
Because Nrf2 was involved in PDGF-induced VSMC migration ( Figure 2 ), Nrf2 in the vessel wall may influence the vascular remodeling in response to injury. To examine endogenous Nrf2 expression and its regulation during injuryinduced remodeling in vivo, we injured the femoral arteries of C57BL/6 mice and examined the temporal pattern of Nrf2 expression by immunofluorescence and immunohistochemical analyses with antibodies against Nrf2 and anti-α-smooth muscle actin, a VSMC marker. Immunofluorescence analysis of uninjured and injured vessels showed that the Nrf2 protein was expressed and colocalized with α-smooth muscle actin in both the vascular media and neointima formed in response to injury ( Figure 5A ). Seven days after the injury, the Nrf2 protein had been highly expressed in VSMCs on the luminal side of the internal elastic lamina during the early stages of neointimal expansion ( Figure 5A and 5B). At 2 weeks, the cells with high-Nrf2 levels were observed in the vascular media and neointima lesions, and by 4 weeks, the Nrf2 protein had returned to the level observed in uninjured vessels ( Figure 5B ).
Nrf2 Reduces Neointimal Hyperplasia in Response to Vascular Injury In Vivo
To directly examine whether the absence of Nrf2 influences the magnitude of injury-induced vascular remodeling, we injured the femoral arteries of Nrf2 −/− and age-and sex-matched wildtype (WT) mice. Four weeks after the injury, the Nrf2 −/− mice showed markedly enhanced neointima formation compared with the WT mice ( Figure 6A ). Quantitative morphometric analysis of the injured vessels revealed a marked reduction in the lumenal area and an increase in the intimal area and intimal/medial ratio with no significant changes in the medial area in injured vessels from the Nrf2 −/− mice compared with those from the WT mice ( Figure 6B ). These morphometric measurements were consistent with marked pathological inward neointimal expansion. We next examined whether the absence of Nrf2 influences ERK1/2 activation and cell proliferation in response to vascular injury in vivo. The Nrf2 −/− mice showed high phosphorylation of ERK1/2 in neointimal lesion at 7 days after wire injury compared with the WT mice ( Figure 6C ). On the contrary, there was no significant difference in neointimal cell density between the Nrf2 −/− mice and the WT mice at 4 weeks after wire injury, although the Nrf2 −/− mice showed enhanced neointimal hyperplasia ( Figure VIII in the online-only Data Supplement). These results suggest that Nrf2 plays an important role in neointimal formation, at least in part, by inhibiting vascular migration that may contribute to vascular remodeling in vivo.
Discussion
The biological significance of Nrf2 in vivo is underscored by observations that Nrf2 −/− mice are much more susceptible to the hepatic toxicity of acetaminophen, 19 pulmonary toxicity of hyperoxia, 20 and stomach carcinogenesis by benzo[a] pyrene. 21 The defense mechanism of Nrf2 against these toxicities is involved in the induction of antioxidant proteins and phase II detoxification enzymes in response to changes in the intracellular redox balance. A role of oxidative stress in neointima thickening and atherosclerosis has been suggested; however, the direct involvement and detailed underlying mechanisms of endogenous Nrf2 are unknown. In this study, we provided novel evidence that the redox-sensitive transcription factor Nrf2 plays an important role in PDGFstimulated VSMC migration by regulating ROS production and elimination, which are critical for neointimal formation and vascular remodeling induced by transluminal arterial injury ( Figure IX in the online-only Data Supplement). Thus, Nrf2 functions as a key regulator for vascular homeostasis. ROS have been proposed as important signaling molecules in many biological events, including VSMC migration and proliferation for tissue repair. 2 However, excess ROS-induced oxidative stress leads to functional alteration of VSMCs, causing the development of neointimal hyperplasia and atherosclerosis after vascular injury. 22 Therefore, ROS regulation is important for vascular homeostasis. PDGF is well known to enhance ROS production in VSMCs and is involved in neointimal formation after balloon angioplasty. 23, 24 The transcription factor Nrf2 plays a central role in a homeostatic mechanism for regulating cellular redox balance. In the present study, we demonstrated a functional role of Nrf2 in PDGF responses using Nrf2 siRNA, which also decreased basal levels of Nqo1, Hmox1, and Txn1 gene expression and significantly enhanced PDGF-stimulated VSMC migration. Consistent with our observations, PDGF-induced VSMC migration is significantly attenuated by pretreatment with various antioxidants, such as NAC, diphenylene iodonium (DPI; a flavoprotein inhibitor), and ebselen (a glutathione peroxidase mimetic). 25 The present study showed that PDGF-induced migration of VSMCs transfected with Nrf2 siRNA was also inhibited by the antioxidant apocynin. Furthermore, adenovirus-mediated Hmox1 overexpression attenuates PDGF-induced transwell movement of VSMCs. 18 These results suggest that endogenous Nrf2 is involved in regulating PDGF-induced ROS-dependent VSMC migration by inducing various antioxidant proteins.
In contrast to migration, Nrf2 siRNA did not enhance PDGF-mediated VSMC proliferation and cell density in the neointima formed in response to vascular injury, as determined by cell numbers. The role of ROS in growth factor-mediated cell proliferation is not completely understood. Several studies have reported that antioxidants, such as NAC, tempol (a superoxide dismutase mimetic), and catalase, reduce agonistdependent proliferation in VSMCs. 10, 26 However, consistent with our data, Freyhaus et al 27 have reported that the NADPH oxidase inhibitor, VAS2870, abolishes PDGFR-β-dependent RASMC migration in a concentration-dependent manner. PDGF-produced ROS are derived from NAD(P)H oxidase. 28 In addition, ROS-evoked oxidative stress induces apoptosis in VSMCs. 29 Taken together, these results indicate that NAD(P) H oxidase-derived ROS are intimately involved in the growth response of VSMCs and, in some cases, cellular apoptosis. Thus, VSMC growth is a balance between proliferation and apoptosis. Our findings suggest that at least endogenous Nrf2 is not involved in PDGF-induced VSMC growth.
In the present study, we demonstrated that stimulation with PDGF promotes ROS production, and ROS levels are enhanced and persist with siRNA depletion of Nrf2. In line with our data, it has been previously shown that pharmacological ROS scavengers or inhibitors of ROS-generating enzymes (eg, NAC and apocynin), reduce PDGF-induced ROS levels in RASMCs. 30 Furthermore, we found that PDGF promotes Nrf2 translocation from the cytoplasm to the nucleus, where it induces gene expression of oxidative stress-responsive proteins, including Nqo1, Hmox1, and Txn1, in actively migrating RASMCs. Signals from ROS insults target the Nrf2-Keap1 complex, dissociating Nrf2 from Keap1. Stabilized Nrf2 then translocates to the nucleus and transactivates its target genes to protect against oxidative stress. 31 These results suggest that Nrf2 inhibits ROS overproduction and accumulation in response to PDGF by inducing antioxidant proteins in VSMCs.
The NAD(P)H oxidase family members, Nox1 and Nox4, are predominately expressed in VSMCs. 28 NAD(P) H oxidase is activated within minutes of PDGF stimulation, and treatment of VSMCs with an NADPH oxidase inhibitor or Nox1 antisense inhibits superoxide anion production and cell migration, 25, 28, 30 suggesting that Nox1 is involved in the response of VSMCs to the major pro-oxidant agonist PDGF. Acute Nox1 activation in VSMCs requires the assembly of subunits of the enzyme complex, which is controlled by Rac1 activation. 2, 9 In the present study, we showed that PDGF stimulation increases Rac1 activity and intracellular ROS levels. Our data provide the first evidence that Nrf2 depletion significantly enhances basal and PDGF-stimulated Rac1 activity in RASMCs. Hydrogen peroxide reportedly activates Rac1 in epithelial cells. 32 The infection of VSMCs with dominant-negative Rac (N 17 -Rac) adenovirus inhibits PDGFinduced VSMC migration. 25 These results suggest that Nrf2 depletion alters the cellular redox balance, thereby affecting Rac1 activity and cell motility. Rho family GTPases (Rac1, cdc42, and Rho) participate in various cellular responses, including reorganization of the actin cytoskeleton, which plays an important role in cell migration. 33 Because Rac1 also plays key roles in the formation of protrusions, such as lamellipodia at the leading edge 33 and PDGF-stimulated cell migration, 34 Nrf2 involvement in actin polymerization will require further study.
Stimulation of cell-surface PDGFR-β with PDGF results in autophosphorylation of the receptor tyrosine residue, facilitating the activation of various downstream transduction pathways, including MAPK-ERK kinase/ERK, MAPK kinase-/ p38 MAPK, and PI3K/Akt. 1, 8 In the present study, Nrf2 siRNA-enhanced PDGF-induced VSMC migration; however, PDGF-mediated PDGFR-β autophosphorylation was not affected by Nrf2 depletion. Importantly, ROS also directly stimulate various downstream kinases of PDGFR-β. Several studies have shown that exogenous application of hydrogen peroxide mediates ERK1/2, 10 p38 MAPK, 35 and Akt 36 phosphorylation. In our study, PDGF activated these reactions, as expected. Interestingly, we found that cells depleted of Nrf2 show sustained ERK1/2 phosphorylation, but not sustained p38 MAPK and Akt phosphorylation, without affecting their peak levels. In vivo, Nrf2-deficient mice showed highly activated ERK1/2 at neointimal lesions in response to vascular injury. VSMC pretreatment with antioxidants reportedly prevents ERK1/2 activation. 10, 37 The present study showed that Nrf2 siRNA-enhanced PDGF-induced ERK1/2 activation is also inhibited by the antioxidants NAC and apocynin in RASMCs. The role of ERK1/2 in PDGF-induced VSMC migration has been demonstrated using PD98059 or U0126, an inhibitor of MAPK-ERK kinase1/2 that activates ERK1/2. 38, 39 These findings suggest that the ROS-ERK1/2 pathway is downstream of PDGFR-β activation involved in VSMC migration followed by neointimal formation, which is regulated by the Nrf2 system. A functional role of Nrf2 in VSMC migration in vivo was underscored by an increase in Nrf2 in intimal α-smooth muscle actin-positive cells, as well as by the enhanced neointimal hyperplasia in injured vessels of the Nrf2 −/− mice. Notably, Nrf2 was increased during the onset of VSMC migration after vascular injury, and this increase disappeared by 4 weeks, suggesting that oxidative stress is induced in the vessel wall during neointimal formation. Several studies have focused on the role of the antioxidant system in the development of atherosclerotic lesions. Sulfasalazine, an immunomodulatory agent, and transresveratrol, a natural polyphenolic stilbene, inhibit intimal hyperplasia by Hmox1 induction, 40, 41 which may be Nrf2 dependent. In contrast, adenovirus-mediated Nrf2 overexpression, which upregulates Hmox1 and glutamate-cysteine ligase, has no apparent effect on the intimal/medial ratio in the rabbit aortic balloon denudation model. 42 However, Nrf2 overexpression by adenovirus infection raises the possibility of affecting the physiological role of Nrf2 by infectioninduced excessive oxidative stress and Nrf2 overexpression without Keap1, an Nrf2 regulatory factor, cotransfection. For these reasons, direct evidence of neointimal formation regulated by endogenous Nrf2 is not yet available. Using genedeficient mice, we are the first to indicate that Nrf2 plays a critical role in neointimal formation and vascular remodeling in vivo, at least in part, by regulating VSMC migration.
In conclusion, the present study reveals novel functions of Nrf2 as a redox-sensitive transcription factor for regulating PDGF-dependent ROS production, thereby regulating VSMC migration and vascular remodeling. Nrf2 knockdown by siRNA significantly attenuated PDGF-induced Nqo1 and Txn1 levels, but not Hmox1 levels in VSMCs (data not shown). Therefore, further studies are required to elucidate the functional roles of the Nrf2 target gene in the blood vessel. Nrf2 also has anti-inflammatory effects in the vasculature. In cultured endothelial cells, Nrf2 overexpression downregulates tumor necrosis factor-α-induced expression of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 at the transcriptional level. 43 These mechanisms may contribute to the repair and maintenance of the functional integrity of blood vessels, providing insight into central roles for Nrf2 in vascular homeostasis. Our findings also provide insight into the Nrf2 system as a potential therapeutic target for various pathophysiologies, such as postangioplasty restenosis, diabetes mellitus, and cancer, as well as atherosclerosis, which are associated with the dysregulation of cell migration as well as oxidative stress and inflammation.
Reactive oxygen species contribute to the development and progression of vascular diseases, such as atherosclerosis. Therefore, cellular redox balance is tightly controlled by various antioxidant systems. Nuclear factor erythroid 2-related factor 2 (Nrf2) plays a critical role in the cellular defense against oxidative stress by transcriptional upregulation of antioxidant proteins. The current study provides compelling evidence that Nrf2 system plays an important role in neointimal formation after vascular injury via regulating platelet-derived growth factor-induced reactive oxygen species-dependent vascular smooth muscle cell migration. Mechanistically, in cultured vascular smooth muscle cells, platelet-derived growth factor promoted nuclear translocation of Nrf2, followed by the induction of target genes. Nrf2 depletion enhances platelet-derived growth factor-induced vascular smooth muscle cell migration by enhancing activation of Rac1 and reactive oxygen species-extracellular signal-regulated kinase pathway. In vivo, the Nrf2-deficient mice showed enhanced neointimal hyperplasia. Our findings provide insight into the Nrf2 system as a potential therapeutic target for vascular smooth muscle cell migration-related vascular diseases, such as atherosclerosis and postangioplasty restenosis.
Significance
